• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-K/A filed by Khosla Ventures Acquisition Co. (Amendment)

    5/12/23 4:13:20 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KVSA alert in real time by email
    10-K/A
    trueFY0001841873YesYesNoNo 0001841873 2022-01-01 2022-12-31 0001841873 2022-06-30 0001841873 us-gaap:CommonClassAMember 2023-03-31 0001841873 us-gaap:CommonClassBMember 2023-03-31 0001841873 kvsa:CommonClassKMember 2023-03-31 xbrli:shares iso4217:USD
    Table of Contents
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    FORM
    10-K/A
    (Amendment No. 1)
     
     
    (Mark One)
    ☒
    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the fiscal year ended December 31, 2022
    OR
     
    ☐
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    FOR THE TRANSITION PERIOD FROM
        
            
        
        
    TO
        
        
            
        
    Commission File
    Number: 001-40131
     
     
    KHOSLA VENTURES ACQUISITION CO.
    (Exact name of Registrant as specified in its Charter)
     
     
     
    Delaware
     
    85-1488707
    (State or other jurisdiction of
    incorporation or organization)
     
    (I.R.S. Employer
    Identification No.)
    2128 Sand Hill Road
    Menlo Park, California
     
    94025
    (Address of principal executive offices)
     
    (Zip Code)
    Registrant’s telephone number, including area code: (650)
    376-8500
     
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange
    on which registered
    Class A common stock, par value $0.0001 per share
     
    KVSA
     
    The Nasdaq Stock Market LLC
    Securities registered pursuant to Section 12(g) of the Act:
    None
    (Title of class)
     
     
    Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    YES  ☐    NO  ☒
    Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    YES  ☐    NO  ☒
    Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    YES  ☒    NO  ☐
    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
    S-T
    (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    YES  ☒    NO  ☐
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
    non-accelerated
    filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
    12b-2
    of the Exchange Act.
     
    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☐
    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  ☐
    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to
    §240.10D-1(b).  ☐
    Indicate by check mark whether the registrant is a shell company (as defined in
    Rule 12b-2
    of the Exchange Act).    YES  ☒    NO  ☐
    As of June 30, 2022, the last business day of the registrant’s most recently completed second fiscal quarter, the closing prices of the registrant’s Class A common stock was $9.75. The aggregate market value of shares of the registrant’s Class A common stock outstanding, other than shares held by persons who may be deemed affiliates of the registrant, computed by reference to the closing price for the shares on June 30, 2022, as reported on the Nasdaq Capital Market was $346,027,500. There is not a public market for the registrant’s Class B common stock, par value $0.0001 per share, and Class K common stock, par value $0.0001 per share, and therefore the aggregate market value of such shares cannot be calculated.
    As of March 31, 2023, 35,490,000 shares of Class A common stock, 5,000,000 shares of Class B common stock and 5,000,000 shares of Class K common stock, par value $0.0001 per share, were issued and outstanding, respectively.
     
    Auditor Firm PCAOB ID:   #243
    Auditor Name:   BDO USA, LLP
    Auditor Location:   McLean, Virginia
     
     
     

    Table of Contents
    EXPLANATORY NOTE
    This Amendment No. 1 to Form
    10-K
    (this “Amendment”) amends the Annual Report on Form
    10-K
    of Khosla Ventures Acquisition Co., a Delaware corporation (the “Company”) for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2023 (the “Original Filing”) for the sole purpose of revising Item 9A. Controls and Procedures to supplement the disclosure relating to the Evaluation of Disclosure Controls and Procedures, to include the previously omitted Management’s Report on Internal Control Over Financial Reporting and to revise Exhibits 31.1 and 31.2 to include certain wording required by 601(b)(31) of Regulation
    S-K
    which was inadvertently omitted by the Company in the Original Filing. Such revised Exhibits have been included in this Amendment as Exhibits 31.3 and 31.4. Because no financial statements are included with this Amendment, paragraph 3 of the certifications in Exhibits 31.3 and 31.4 has been omitted.
    In addition, as required by Rule
    12b-15
    under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by the registrant’s principal executive officer and principal financial officer are filed as exhibits to this Amendment.
    No other changes have been made to the Original Filing. This Amendment does not reflect events that may have occurred subsequent to the original filing date, and does not otherwise modify or update in any way the disclosures made in the Original Filing.


    Part II

     

    Item 9A.

    Controls and Procedures.

    Evaluation of disclosure controls and procedures

    Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

    Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal year ended December 31, 2022, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act.

    Based on this evaluation, our principal executive officer and principal financial and accounting officer have concluded that, as of December 31, 2022, our disclosure controls and procedures were not effective due to material weaknesses in internal controls over financial reporting related to inaccurate accounting. Management identified errors in its historical financial statements related to the accounting for the Class A common stock, the Class K founder shares, and cash flow statement presentation. Because the Class A common stock issued in the Company’s initial public offering (the “IPO”) can be redeemed or become redeemable subject to the occurrence of future events considered outside of the Company’s control, the Company should have classified all of these redeemable shares in temporary equity and remeasured these redeemable shares to their redemption value (i.e., $10.00 per share) as of the end of the first reporting period after the date of the Company’s IPO. Management also concluded that it incorrectly accounted for the Class K founder shares as permanent equity versus derivative liabilities. Management also concluded that it incorrectly presented the gain on marketable securities (net), dividends and interest, held in the Trust Account as operating activities in cash flow statement versus investing activities.

    To address these material weaknesses, management has devoted, and plans to continue to devote, significant effort and resources to the remediation and improvement of its internal control over financial reporting and to provide processes and controls over the internal communications within the Company, financial advisors and independent registered public accounting firm. While we have processes to identify and appropriately apply applicable accounting requirements, we plan to enhance these processes to better evaluate our research and understanding of the nuances of the complex accounting standards that apply to our financial statements. We plan to include providing enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding complex accounting applications. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects. Following identification of the material weaknesses and prior to filing the Annual Report on Form 10-K, we completed substantive procedures for the year ended December 31, 2022. Based on these procedures, management believes that our financial statements included in this Form 10-K have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Our principal executive officer and principal financial and accounting officer have certified that, based on their knowledge, the financial statements, and other financial information included in the Form 10-K, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in the Form 10-K.

    Management’s annual report on internal control over financial reporting

    Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed by, or under the supervision of, our principal executive officer and principal financial and accounting officer, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP and includes those policies and procedures that:

     

      •  

    pertain to the maintenance of records that accurately and fairly reflect in reasonable detail the transactions and dispositions of the assets of our company;


      •  

    provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

     

      •  

    provide reasonable assurances regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material adverse effect on our financial statements.

    Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2022 based on the criteria established in “Internal Control – Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

    Based on this evaluation, our principal executive officer and principal financial and accounting officer have concluded that during the period covered by this report, our internal control over financial reporting was not effective due to the material weaknesses described above.

    Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

    Attestation report of the registered public accounting firm

    This Amendment No. 1 to Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm due to an exemption established by the Jumpstart Our Business Startups Act of 2012 for “emerging growth companies.”

    Changes in internal control over financial reporting

    During the year ended December 31, 2022, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, as the circumstances that led to the material weaknesses described above had not yet been identified. We are in the process of implementing changes to our internal control over financial reporting to remediate such material weaknesses, as more fully described above. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.


    PART IV

     

    Item 15.

    Exhibits and Financial Statement Schedules

    (a)(1) Financial Statements.

    The financial statements required by Item 15(a) were filed as part of the Original Filing on pages F-1 through F-23 in the Original Filing.

    (a)(2) Financial Statement Schedules.

    All financial statement schedules are omitted because they are not applicable or the amounts are immaterial and not required, or the required information is presented in the financial statements and notes thereto.

    (a)(3) Exhibits.

    The following is a list of exhibits filed or furnished, or incorporated by reference into, as part of this Annual Report on Form 10-K.

     

              Incorporated by Reference    Filed/
    Furnished
    Herewith
     

    Exhibit

    Number

      

    Exhibit Description

       Form    File No.    Exhibit    Filing
    Date
      1.1    Underwriting Agreement, dated March 3, 2021, among the Company and Goldman Sachs & Co. LLC, as representative of the several underwriters    8-K    001-40131    1.1    3/9/21   
      3.1    Second Amended and Restated Certificate of Incorporation, dated March 4, 2021    8-K    001-40131    3.1    3/9/21   
      3.3    Bylaws    S-1    333-253096    3.3    2/12/21   
      4.1    Specimen Class A Common Stock Certificate    S-1    333-253096    4.1    2/12/21   
      4.2    Description of Capital Stock    10-K    001-40131    4.2    4/1/22   
    10.1    Investment Management Trust Agreement, dated March 3, 2021, between the Company and Continental Stock Transfer & Trust Company, as trustee    8-K    001-40131    10.1    3/9/21   
    10.2    Private Placement Shares Agreement, dated March 3, 2021, between the Company and the Sponsor    8-K    001-40131    10.2    3/9/21   
    10.3    Registration Rights Agreement, dated March 3, 2021, among the Company and certain security holders named therein    8-K    001-40131    10.3    3/9/21   
    10.4    Forward Purchase Agreement, dated March 3, 2021, among the Company and the Sponsor    8-K    001-40131    10.4    3/9/21   


              Incorporated by Reference    Filed/
    Furnished
    Herewith
     

    Exhibit

    Number

      

    Exhibit Description

       Form    File No.    Exhibit    Filing
    Date
    10.5#    Letter Agreement, dated March 3, 2021, among the Company, the Sponsor, Vinod Khosla, Samir Kaul, Peter Buckland, Jagdeep Singh, Derek Anthony West, Rajiv Shah, Molly Coye, Mario Schlosser and Dmitri Shklovsky    8-K    001-40131    10.5    3/9/21   
    10.6#    Form of Indemnity Agreement, dated March 3, 2021, between the Company and each of its officers and directors    8-K    001-40131    10.6    3/9/21   
    10.7    Voting Agreement, dated as of March 26, 2021    8-K    001-40131    10.1    3/26/21   
    10.8    Promissory Note, dated as of January 19, 2021, issued to the sponsor    S-1    333-253096    10.5    2/12/21   
    10.9    Securities Subscription Agreement, dated January 22, 2021, between the Registrant and the sponsor    S-1    333-253096    10.6    2/12/21   


              Incorporated by Reference    Filed/
    Furnished
    Herewith

    Exhibit

    Number

      

    Exhibit Description

       Form    File No.    Exhibit    Filing
    Date
      31.1    Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a)    10-K    001-40131    31.1    3/31/2023   
      31.2    Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a)    10-K    001-40131    31.2    3/31/2023   
      31.3    Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a)                *
      31.4    Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a)                *
      32.1    Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350    10-K    001-40131    32.1    3/31/2023   
      32.2    Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350    10-K    001-40131    32.2    3/31/2023   
      32.3    Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350                **
      32.4    Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350                **
    101.INS    Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document                *
    101.SCH    Inline XBRL Taxonomy Extension Schema Document                *
    101.CAL    Inline XBRL Taxonomy Extension Calculation Linkbase Document                *
    101.DEF    Inline XBRL Taxonomy Extension Definition Linkbase Document                *
    101.LAB    Inline XBRL Taxonomy Extension Label Linkbase Document                *
    101.PRE    Inline XBRL Taxonomy Extension Presentation Linkbase Document                *
    104    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)                *

     

    *

    Filed herewith.

    **

    Furnished herewith.


    SIGNATURES

    Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

        KHOSLA VENTURES ACQUISITION CO.
    Date: May 12, 2023     By:   /s/ Samir Kaul
                Samir Kaul
                Chief Executive Officer and President

     

    Date: May 12, 2023     By:   /s/ Peter Buckland
                Peter Buckland
                Chief Financial Officer

     

    Get the next $KVSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KVSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Khosla Ventures Acquisition Co. Announces Redemption of Public Shares and Subsequent Dissolution

    MENLO PARK, Calif., Dec. 4, 2023 /PRNewswire/ -- Khosla Ventures Acquisition Co. (the "Company") (NASDAQ:KVSA) today announced that it will redeem all of its outstanding shares of Class A common stock that were issued in its initial public offering and not previously redeemed (the "public shares"), effective as of the close of business on December 11, 2023, as the Company will not consummate an initial business combination on or prior to December 8, 2023. Pursuant to the Amended and Restated Certificate of Incorporation, if the Company does not complete its initial business combination by December 8, 2023, then the Company will: (i) cease all operations except for the purpose of winding up,

    12/4/23 5:38:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valo Health and Khosla Ventures Acquisition Co. Mutually Agree to Terminate Business Combination Agreement

    BOSTON and MENLO PARK, Calif., Nov. 15, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process and Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by affiliates of Khosla Ventures, LLC, announced today that both companies have mutually agreed to terminate their previously announced agreement and plan of merger (the "Business Combination Agreement"), effective immediately. Both parties decided to terminate the Business Combination based on current market conditions, particularly in the biot

    11/15/21 5:40:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valo Health and Khosla Ventures Acquisition Co. Announce Additional PIPE Commitments

    BOSTON and MENLO PARK, Calif., Nov. 9, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, and Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that the private placement of common stock ("PIPE") investment in connection with their previously announced business combination had expanded from $168.5M to over $200M exceeding initial targets.

    11/9/21 4:00:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    SEC Filings

    View All

    SEC Form 15-12G filed by Khosla Ventures Acquisition Co.

    15-12G - Khosla Ventures Acquisition Co. (0001841873) (Filer)

    12/21/23 9:20:51 AM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Khosla Ventures Acquisition Co. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Khosla Ventures Acquisition Co. (0001841873) (Filer)

    12/12/23 5:25:01 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Khosla Ventures Acquisition Co.

    25-NSE - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    12/11/23 5:05:42 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    Financials

    Live finance-specific insights

    View All

    Khosla Ventures Acquisition Co. Announces Planned Transfer of Listing to NYSE in Connection with its Proposed Business Combination with Valo Health

    BOSTON and MENLO PARK, Calif., Oct. 28, 2021 /PRNewswire/ -- Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that it will voluntarily transfer the listing of its Class A common stock, par value $0.0001 per share ("Class A Common Stock"), from the Nasdaq Capital Market ("Nasdaq") to the New York Stock Exchange ("NYSE") in connection with, and following the closing of, the previously announced business combination (the "Business Combination") with Valo Health, Inc. ("Valo"), the wholly owned subsidiary of Valo Health, LLC ("Valo Health"). The shares of Class A Co

    10/28/21 7:13:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)

    SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/14/24 4:55:28 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)

    SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/12/24 12:56:18 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Khosla Ventures Acquisition Co.

    SC 13G - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/14/23 4:18:34 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care